Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib, Randomized, Double-Blind, Placebo Controlled, Sequential Study of Single Oral Doses of M5717 to Explore the Chemoprophylactic Activity of M5717 in a Controlled PISPZ Challenge Model in Healthy Participants

Next Previous
Search
Trial Profile

A Phase Ib, Randomized, Double-Blind, Placebo Controlled, Sequential Study of Single Oral Doses of M5717 to Explore the Chemoprophylactic Activity of M5717 in a Controlled PISPZ Challenge Model in Healthy Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabamiquine (Primary) ; Malaria vaccine live unattenuated-Sanaria
  • Indications Falciparum malaria
  • Focus Therapeutic Use
  • Sponsors Merck KGaA

    • Most Recent Events

    • 07 Nov 2023 Number of treatment arms are increased from 2 to 10 by the addition of 8 more experimental arms of various increasing dose levels for early and late liver stages. Four more Primary end points are added.
    • 14 Jun 2021 Status changed from recruiting to completed.
    • 15 Dec 2020 Planned number of patients changed from 80 to 50.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top